Advisor Information
Song-young Park
Presentation Type
Poster
Start Date
1-3-2019 12:30 PM
End Date
1-3-2019 1:45 PM
Abstract
Peripheral arterial disease (PAD) is an atherosclerotic disease that affects the arteries in the legs, causing decreased blood flow and oxygen transfer capacity to the skeletal muscle. This ischemia in the skeletal muscle in PAD patients may result in increased inflammation and mitochondrial dysfunction due to increased reactive oxygen species (ROS) production. Inflammation and ROS production have been shown to attenuate vascular function in PAD patients Mitochondrial-targeted antioxidants (such as MitoQ) have been shown to combat ROS and inflammation in various diseases.
Purpose: We sought to examine the impacts of MitoQ intake on vascular function measurements in PAD patients. We hypothesized that MitoQ intake would improve vascular function..
Methods: PAD patients (stage II-III, age around 73) had measurements taken pre- and post-MitoQ intake, including heart rate (HR), BP, endothelial function, arterial stiffness, and central pressure analysis.
Results: After MitoQ intake, there were decreases in HR (Δ-3.5bpm) peripheral BP (Δ-9/-4.5 mmHg), and central BP (Δ-8/-2.5 mmHg). Carotid-to-radial pulse wave velocity increased (Δ0.5 m/s) and augmentation index increased (Δ12.75%) after MitoQ intake. There were increases in both endothelial function (Δ0.33%) and deceleration time (Δ25ms) along with a decrease in augmented pressure (Δ-.7.5) after MitoQ intake.
Conclusion: This study showed that utilization of MitoQ may potentially have significant impacts on improving central and peripheral vascular function and may be useful as a therapeutic treatment for PAD patients. However, there should be future studies with more participants to demonstrate the effectiveness of MitoQ on vascular function in PAD patients.
IMPACTS OF MITOCHONDRIAL-TARGETED ANTIOXIDANT (MitoQ) ON SKELETAL MUSCLE MITOCHONDRIAL FUNCTION IN PERIPHERAL ARTERIAL DISEASE PATIENTS
Peripheral arterial disease (PAD) is an atherosclerotic disease that affects the arteries in the legs, causing decreased blood flow and oxygen transfer capacity to the skeletal muscle. This ischemia in the skeletal muscle in PAD patients may result in increased inflammation and mitochondrial dysfunction due to increased reactive oxygen species (ROS) production. Inflammation and ROS production have been shown to attenuate vascular function in PAD patients Mitochondrial-targeted antioxidants (such as MitoQ) have been shown to combat ROS and inflammation in various diseases.
Purpose: We sought to examine the impacts of MitoQ intake on vascular function measurements in PAD patients. We hypothesized that MitoQ intake would improve vascular function..
Methods: PAD patients (stage II-III, age around 73) had measurements taken pre- and post-MitoQ intake, including heart rate (HR), BP, endothelial function, arterial stiffness, and central pressure analysis.
Results: After MitoQ intake, there were decreases in HR (Δ-3.5bpm) peripheral BP (Δ-9/-4.5 mmHg), and central BP (Δ-8/-2.5 mmHg). Carotid-to-radial pulse wave velocity increased (Δ0.5 m/s) and augmentation index increased (Δ12.75%) after MitoQ intake. There were increases in both endothelial function (Δ0.33%) and deceleration time (Δ25ms) along with a decrease in augmented pressure (Δ-.7.5) after MitoQ intake.
Conclusion: This study showed that utilization of MitoQ may potentially have significant impacts on improving central and peripheral vascular function and may be useful as a therapeutic treatment for PAD patients. However, there should be future studies with more participants to demonstrate the effectiveness of MitoQ on vascular function in PAD patients.